Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

April 30, 2017

Conditions

Healthy

Interventions

DRUG

GLA5PR GLARS-NF3 tablet 300mg

A new formulation(3rd.) of Pregabalin CR tablet

DRUG

GLA5PR GLARS-NF1 tablet 300mg

A new formulation(1st.) of Pregabalin CR tablet

Trial Locations (1)

Chonbuk National University Hospital, Jeonju